Zoetis Inc. (NYSE:ZTS) Shares Sold by Diversified Trust Co

Diversified Trust Co lowered its holdings in Zoetis Inc. (NYSE:ZTS) by 8.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,455 shares of the company’s stock after selling 1,368 shares during the period. Diversified Trust Co’s holdings in Zoetis were worth $2,518,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Darwin Wealth Management LLC bought a new position in shares of Zoetis in the third quarter valued at $31,000. First Personal Financial Services acquired a new stake in shares of Zoetis during the third quarter worth $33,000. Capital Performance Advisors LLP acquired a new stake in shares of Zoetis during the third quarter worth $33,000. Dunhill Financial LLC lifted its holdings in shares of Zoetis by 80.6% during the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after purchasing an additional 75 shares during the last quarter. Finally, Quarry LP boosted its position in shares of Zoetis by 273.2% in the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after purchasing an additional 153 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Zoetis Trading Down 1.3 %

NYSE:ZTS opened at $163.68 on Wednesday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The company has a market capitalization of $73.85 billion, a P/E ratio of 30.77, a P/E/G ratio of 2.91 and a beta of 0.89. The stock’s 50 day moving average price is $172.71 and its 200 day moving average price is $180.42. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.53.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. The business had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. Zoetis’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same quarter last year, the firm earned $1.36 EPS. On average, research analysts forecast that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be issued a dividend of $0.50 per share. This is a positive change from Zoetis’s previous quarterly dividend of $0.43. The ex-dividend date of this dividend is Tuesday, January 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.22%. Zoetis’s dividend payout ratio is currently 37.59%.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. JPMorgan Chase & Co. upped their price objective on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. UBS Group initiated coverage on shares of Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective on the stock. Stifel Nicolaus decreased their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday. Finally, Leerink Partners assumed coverage on Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target on the stock. One investment analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $211.89.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.